EGFR and non-small cell lung carcinoma: In summary, this is an analysis reporting the CNS efficacy of furmonertinib with different doses in EGFR T790M mutated NSCLC patients and reveals that furmonertinib of 80 mg orally once daily or higher is effective in CNS metastatic patients.